| Literature DB >> 24784232 |
David J Marchant1, Caroline L Bellac2, Theo J Moraes3, Samuel J Wadsworth4, Antoine Dufour2, Georgina S Butler2, Leanne M Bilawchuk5, Reid G Hendry5, A Gordon Robertson6, Caroline T Cheung4, Julie Ng4, Lisa Ang4, Zongshu Luo4, Karl Heilbron4, Michael J Norris3, Wenming Duan3, Taylor Bucyk5, Andrei Karpov4, Laurent Devel7, Dimitris Georgiadis8, Richard G Hegele3, Honglin Luo4, David J Granville4, Vincent Dive7, Bruce M McManus9, Christopher M Overall10.
Abstract
Interferon-α (IFN-α) is essential for antiviral immunity, but in the absence of matrix metalloproteinase-12 (MMP-12) or IκBα (encoded by NFKBIA) we show that IFN-α is retained in the cytosol of virus-infected cells and is not secreted. Our findings suggest that activated IκBα mediates the export of IFN-α from virus-infected cells and that the inability of cells in Mmp12(-/-) but not wild-type mice to express IκBα and thus export IFN-α makes coxsackievirus type B3 infection lethal and renders respiratory syncytial virus more pathogenic. We show here that after macrophage secretion, MMP-12 is transported into virus-infected cells. In HeLa cells MMP-12 is also translocated to the nucleus, where it binds to the NFKBIA promoter, driving transcription. We also identified dual-regulated substrates that are repressed both by MMP-12 binding to the substrate's gene exons and by MMP-12-mediated cleavage of the substrate protein itself. Whereas intracellular MMP-12 mediates NFKBIA transcription, leading to IFN-α secretion and host protection, extracellular MMP-12 cleaves off the IFN-α receptor 2 binding site of systemic IFN-α, preventing an unchecked immune response. Consistent with an unexpected role for MMP-12 in clearing systemic IFN-α, treatment of coxsackievirus type B3-infected wild-type mice with a membrane-impermeable MMP-12 inhibitor elevates systemic IFN-α levels and reduces viral replication in pancreas while sparing intracellular MMP-12. These findings suggest that inhibiting extracellular MMP-12 could be a new avenue for the development of antiviral treatments.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24784232 DOI: 10.1038/nm.3508
Source DB: PubMed Journal: Nat Med ISSN: 1078-8956 Impact factor: 53.440